Do You Have to Take Allergy Shots Forever? The 3-5 Year Arc Explained

After completing a full 3-5 year allergy shot course, most patients retain meaningful symptom relief for years without any further treatment. Durham et al. (NEJM, 1999) demonstrated that benefits persist for at least 3 years after stopping a completed grass pollen immunotherapy course. The PAT study showed disease-modifying effects in children lasting 7 or more years post-treatment. Post-discontinuation monitoring typically involves clinical reassessment every 6-12 months for the first 1-2 years to detect symptom recurrence early. Approximately 10-25% of patients experience some degree of symptom return within 3-5 years of stopping, at which point a second immunotherapy course is an option. During the post-stop period, patients may resume antihistamines or nasal steroids on an as-needed basis — but many find their medication needs significantly reduced compared to pre-immunotherapy baseline.

Stopping allergy shots prematurely at 1-2 years provides some benefit, but significantly increases the risk of symptom recurrence compared to completing the full 3-5 year course. Research by Eng et al. (Clinical and Experimental Allergy, 2006) showed that patients who complete a full course have substantially better long-term outcomes than those who discontinue early. The first year of treatment, particularly the build-up phase, is when the foundational immune reprogramming begins — but the sustained maintenance phase is required for durable tolerance induction. If circumstances require stopping early (pregnancy, relocation, financial barriers), discuss the timing with your allergist, who can advise on whether you've reached a phase where stopping is least detrimental. Some partial benefit is retained even from incomplete courses, but the risk of full symptom recurrence within 1-2 years of early stopping is substantially higher than after completing the full protocol.

The primary clinical indicator that allergy shots are working is significant symptom reduction during your peak allergen season, with notably less need for rescue medications (antihistamines, nasal sprays) compared to your pre-treatment baseline. Most patients notice meaningful improvement between 3 and 12 months into treatment, with full benefit typically developing over 12-18 months. At the end of each allergen season, compare your symptom burden and medication use to your pre-treatment diary — this comparison is how allergists and patients jointly evaluate whether the treatment is achieving its goals. Objective measures can supplement this assessment: skin prick test wheal reduction, declining serum-specific IgE levels, and rising IgG4 blocking antibodies all indicate immunological response. Your allergist will conduct formal reassessment around years 3-5 of maintenance to evaluate whether the goals for discontinuation have been met.

Benefits from a completed allergy shot course do not last indefinitely for everyone, but they can persist for many years — substantially longer than what medications provide. Durham et al. (NEJM, 1999) showed lasting benefit at 3 years post-treatment, and the PAT study (Jacobsen et al., Allergy, 2007) demonstrated effects persisting beyond 7 years. The immune changes from immunotherapy — specifically IgG4 blocking antibodies, regulatory T-cell induction, and IgE downregulation — appear to be maintained by the natural allergen exposures that continue after treatment ends, provided the course was completed and tolerance was fully established. The 10-25% relapse rate means that a meaningful minority of patients experience symptom return, typically gradual rather than abrupt. For these patients, a second immunotherapy course is generally effective. The honest answer: most patients retain benefit for 3-7 years; some for longer; a minority need retreatment.

Starting allergy shots with a known 2-year commitment limit is worth discussing with your allergist before beginning, rather than discovering mid-treatment. Two years of treatment — including build-up and at least 1-1.5 years of maintenance — provides partial but real benefit. Many patients notice significant symptom improvement within the first 1-2 years. The concern is that stopping at 2 years rather than 3-5 years substantially reduces the likelihood of durable post-treatment benefit: relapse rates at 2 years post-premature-discontinuation are significantly higher than after completing a full course. If the barrier to finishing is the weekly clinic trip rather than the treatment itself, an at-home option such as Curex lets you self-administer the same shots on the same schedule — often making it realistic to complete the full 3-5 year course you would otherwise cut short. Whatever you choose, partial treatment is generally better than no treatment.

Yes — a second allergy immunotherapy course is an established option for patients whose symptoms return after completing their first course. Clinical practice data support the effectiveness of retreatment, with most patients achieving comparable benefit to their initial course. The decision to start a second course is made the same way as the first: your allergist assesses current allergen sensitization (which may have shifted), symptom severity and impact on quality of life, and whether pharmacotherapy is providing adequate control. Some allergists recommend a re-testing visit to confirm current sensitization profile before designing the second course extract. There is no established waiting period required between a completed first course and a second course, though most patients and allergists prefer to observe for 1-2 seasons of recurrent symptoms before recommitting to another 3-5 year protocol.